Skip to Content

Cilnidipine

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

C08CA14

CAS registry number (Chemical Abstracts Service)

0132203-70-4

Chemical Formula

C27-H28-N2-O7

Molecular Weight

493

Therapeutic Categories

Antihypertensive agent

Calcium channel blocker

Chemical Name

(±)-(E)-Cinnamyl 2-metoxyetyl 1,4-dihydro-2,6-dimetyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

Foreign Names

  • Cilnidipinum (Latin)
  • Cilnidipin (German)
  • Cilnidipine (French)
  • Cilnidipino (Spanish)

Generic Names

  • Cilnidipine (OS: JAN)
  • FRC 8653 (IS)
  • Cilnidipine (PH: JP XVII)

Brand Names

  • Atedio [+ Valsartan]
    EA Pharma, Japan
  • Atelec
    Ajinomoto Pharmaceutical, Vietnam; EA Pharma, Japan
  • Cilnidipine
    Daiko Seiyaku, Japan; Nihon Generic, Japan; Sawai Seiyaku, Japan; Shiono Kemikaru, Japan; Takeda Teva Pharma, Japan
  • Cilnidipine - Xinya
    New Asiatic Pharm, China
  • Jiuyue
    Jiu Dian Pharmaceutical, China
  • Nexovas
    Macleods, India
  • Nexovas-CH [+ Chlortalidone]
    Macleods, India
  • Nexovas-O [+ Olmesartan Medoxomil]
    Macleods, India
  • Xi Le
    Tai Sheng Pharmaceutical, China
  • Zhi Xin
    Feng Yuan Pharm, China

Glossary

TermDefinition
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide